Data presented support broad potential therapeutic applications of MRT-6160 in a variety of autoimmune and inflammatory disorders driven by underlying dysregulation of T- and B-cells, including rheumatoid arthritis Investigational New Drug filing for MRT-6160 expected in 1H 2024 Data will be presented during Poster Session A on Sunday, November 12, 2023 from 9:00-11:00 am PT BOSTON, Nov.

所提供的数据支持MRT-6160在由T细胞和B细胞潜在失调驱动的各种自身免疫性和炎性疾病中的广泛潜在治疗应用，包括类风湿性关节炎2024年1月1日预计MRT-6160的研究性新药申请将在2023年11月12日星期日上午9:00-11:00在波士顿11月12日海报会议期间呈现。

07, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the company will present preclinical data at the American College of Rheumatology (ACR) Convergence Annual Meeting held November 10-15 in San Diego, CA.

072023（GLOBE NEWSWIRE）-Monte Rosa Therapeutics，Inc。（纳斯达克股票代码：GLUE），一家开发新型分子胶降解剂（MGD）药物的临床阶段生物技术公司，今天宣布该公司将提供临床前数据。美国风湿病学会（ACR）会聚年会于11月10日至15日在加利福尼亚州圣地亚哥举行。

The data demonstrate that MRT-6160, a novel, highly selective MGD targeting VAV1, attenuated disease progression in a murine collagen-induced arthritis (CIA) model. In vitro, MRT-6160 induced selective degradation of VAV1, and attenuated TCR- and BCR-mediated activation and function of primary human T- and B-cells.

数据表明MRT-6160是一种新型，高选择性MGD靶向VAV1，减弱了小鼠胶原诱导的关节炎（CIA）模型中的疾病进展。在体外，MRT-6160诱导VAV1的选择性降解，并减弱TCR和BCR介导的原代人T细胞和B细胞的活化和功能。

In the CIA model, oral dosing of MRT-6160 elicited rapid VAV1 degradation across multiple tissues in a dose-dependent manner. Over the course of 20 days, MRT-6160 significantly decreased disease progression and endpoint functional scores compared to vehicle and showed a trend towards superior activity compared to an anti-TNF antibody.

在CIA模型中，口服MRT-6160以剂量依赖性方式引起跨多个组织的快速VAV1降解。在20天的过程中，与载体相比，MRT-6160显着降低疾病进展和终点功能评分，并且与抗TNF抗体相比显示出优异活性的趋势。

“We are highly encouraged by these preclinical data, which we believe further establish the importance of VAV1 as a potential therapeutic target in T- and B-cell mediated autoimmunity, as well as MRT-6160’s potential to broadly treat autoimmune and inflammatory diseases including rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, psoriasis and other autoimmune diseases,” said Owen Wal.

“我们对这些临床前数据非常鼓舞，我们相信VAV1作为T细胞和B细胞介导的自身免疫的潜在治疗靶点的重要性，以及MRT-6160广泛治疗自身免疫和炎症疾病的潜力，包括类风湿性关节炎，多发性硬化症，炎症性肠病，牛皮癣和其他自身免疫性疾病“欧文·沃尔说。